JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Riley, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Riley, R. F.
Journal of Pharmacology And Experimental Therapeutics, Vol. 99, Issue 3, 329-333, 1950
Copyright © 1950 by American Society for Pharmacology and Experimental Therapeutics

METABOLISM OF MYANESIN (3-(O-TOLOXY)-1, 2-PROPANEDIOL)

Richard F. Riley 1

1 University of California Atomic Energy Project, Post Office Box 31, Beverly Hills, California

Of an oral dose of 2 gm. of Myanesin, 28 per cent was excreted in the urine in 24 hours as beta-(o-toloxy)-lactic acid; 54 per cent of a 4 gm. dose was similarly eliminated. Elimination of beta-(o-toloxy)-lactic acid was complete in 24 hours after the larger dose.

No evidence was found to indicate that appreciable quantities of free Myanesin are excreted in the urine of humans. No significant amounts of the drug are degraded to o-toloxyacetic acid or to o-cresol in man or in rats.

Tissue storage of Myanesin as fatty acid esters is not appreciable.

Submitted on March 15, 1950






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1950 by the American Society for Pharmacology and Experimental Therapeutics.